MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that the treatment of thyroid nodules with Theraclion’s Echopulse technology will now be reimbursed by one of Germany’s leading insurance companies.
In Germany, approximately 100,000 thyroid surgeries and 50,000 thyroid radioiodine procedures are performed annually. Many of these procedures could be replaced by a non-invasive approach using the Echopulse system, eliminating the need for general anesthesia, hospitalization and scarring. In addition, after thyroidectomies, many patients require life-long medication. Echopulse treatment offers a non-invasive, local procedure, preserving the natural function of the thyroid. In addition to the clinical benefits for the patient, Echopulse offers an economically appealing option to healthcare systems, as the outpatient procedure requires no surgical suite, nor the intensive human resources typically associated with surgery.
"This first coverage of Echopulse treatment for thyroid nodules is an important impulse for patient access to the technology," says Dr. Hakman, head of Drs. Hakman – Praxis für Nuklearmedizin in Paderborn, Germany. "Providing the possibility for non-invasive treatment for patients with thyroid nodules is not only a great benefit for those who are concerned but also avoids unnecessary costs to the healthcare system in general as costly surgical interventions will be avoided."
David Caumartin, CEO of Theraclion adds: “This first coverage is a breakthrough for German patients suffering from benign but symptomatic thyroid nodules who want to avoid the ablation of their thyroid. This step is the basis for patient access to Echopulse treatment which will be provided by the two new German thyroid centers opening in a few weeks."
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
Mnemonic: ALTHE - ISIN Code: FR0010120402